Delisting risk
Liminatus Pharma Class A (LIMN)
Develops oncology antibodies and autologous CAR-T candidates through a license- and partner-dependent model.
$3.88
Pre-market+0.04 (+1.04%)
At close$3.84(+5.35%)
Something off on this page? Send us feedback.
EPSReportedEstimate
———Oct '25Nov '25Mar '26May '26Aug '26
Reported———−$0.05−$0.07−$0.03−$0.03−$1.50
Estimate————————
Surprise————————
RevenueReportedEstimate
———Oct '25Nov '25Mar '26May '26Aug '26
Reported————————
Estimate————————
Surprise————————
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Aug 2026 | — | −$1.50 | — |
| Jun 2026 | — | — | — |
| May 2026 | — | −$0.03 | — |
| Mar 2026 | — | −$0.03 | — |
| Nov 2025 | — | −$0.07 | — |
The latest year is open to everyone — the 1 quarter behind it read with an account. Sign in | |||
| Oct 2025 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | — | −$1.50 | — | — | — | — | −6.7% |
| Jun 30, 2026 | — | — | — | — | — | — | — |
| May 15, 2026 | — | −$0.03 | — | — | — | — | +3.9% |
| Mar 31, 2026 | — | −$0.03 | — | — | — | — | −0.6% |
| Nov 13, 2025 | — | −$0.07 | — | — | — | — | 0.0% |
The latest year is open to everyone — the 1 quarter behind it read with an account. Sign in | |||||||
| Oct 3, 2025 | |||||||